575 related articles for article (PubMed ID: 15128793)
41. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
42. H2-M3-restricted CD8+ T cells augment CD4+ T-cell responses by promoting DC maturation.
Chow MT; Teh HS
Eur J Immunol; 2010 May; 40(5):1408-17. PubMed ID: 20162552
[TBL] [Abstract][Full Text] [Related]
43. Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading.
Robson NC; Beacock-Sharp H; Donachie AM; Mowat AM
Immunology; 2003 Jul; 109(3):374-83. PubMed ID: 12807483
[TBL] [Abstract][Full Text] [Related]
44. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
[TBL] [Abstract][Full Text] [Related]
45. Glycoprotein 96-activated dendritic cells induce a CD8-biased T cell response.
Ramirez SR; Singh-Jasuja H; Warger T; Braedel-Ruoff S; Hilf N; Wiemann K; Rammensee HG; Schild H
Cell Stress Chaperones; 2005; 10(3):221-9. PubMed ID: 16184767
[TBL] [Abstract][Full Text] [Related]
46. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
47. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes.
Blohm U; Roth E; Brommer K; Dumrese T; Rosenthal FM; Pircher H
J Immunol; 2002 Nov; 169(10):5522-30. PubMed ID: 12421928
[TBL] [Abstract][Full Text] [Related]
48. Transient loss of MHC class I tetramer binding after CD8+ T cell activation reflects altered T cell effector function.
Drake DR; Ream RM; Lawrence CW; Braciale TJ
J Immunol; 2005 Aug; 175(3):1507-15. PubMed ID: 16034088
[TBL] [Abstract][Full Text] [Related]
49. Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.
Ho NI; Camps MGM; de Haas EFE; Ossendorp F
Eur J Immunol; 2018 Jul; 48(7):1164-1173. PubMed ID: 29676785
[TBL] [Abstract][Full Text] [Related]
50. CD4+ T cells mature in the absence of MHC class I and class II expression in Ly-6A.2 transgenic mice.
Henderson SC; Berezovskaya A; English A; Palliser D; Rock KL; Bamezai A
J Immunol; 1998 Jul; 161(1):175-82. PubMed ID: 9647222
[TBL] [Abstract][Full Text] [Related]
51. Bacterial heat shock proteins enhance class II MHC antigen processing and presentation of chaperoned peptides to CD4+ T cells.
Tobian AA; Canaday DH; Harding CV
J Immunol; 2004 Oct; 173(8):5130-7. PubMed ID: 15470057
[TBL] [Abstract][Full Text] [Related]
52. Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation.
Meyer zu Hörste G; Heidenreich H; Mausberg AK; Lehmann HC; ten Asbroek AL; Saavedra JT; Baas F; Hartung HP; Wiendl H; Kieseier BC
Neurobiol Dis; 2010 Feb; 37(2):483-90. PubMed ID: 19914379
[TBL] [Abstract][Full Text] [Related]
53. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
[TBL] [Abstract][Full Text] [Related]
54. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
55. IL-10 promotes homeostatic proliferation of human CD8(+) memory T cells and, when produced by CD1c(+) DCs, shapes naive CD8(+) T-cell priming.
Nizzoli G; Larghi P; Paroni M; Crosti MC; Moro M; Neddermann P; Caprioli F; Pagani M; De Francesco R; Abrignani S; Geginat J
Eur J Immunol; 2016 Jul; 46(7):1622-32. PubMed ID: 27129615
[TBL] [Abstract][Full Text] [Related]
56. Cross-positive selection of thymocytes expressing a single TCR by multiple major histocompatibility complex molecules of both classes: implications for CD4+ versus CD8+ lineage commitment.
Eshima K; Suzuki H; Shinohara N
J Immunol; 2006 Feb; 176(3):1628-36. PubMed ID: 16424192
[TBL] [Abstract][Full Text] [Related]
57. CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses.
Umeshappa CS; Huang H; Xie Y; Wei Y; Mulligan SJ; Deng Y; Xiang J
J Immunol; 2009 Jan; 182(1):193-206. PubMed ID: 19109150
[TBL] [Abstract][Full Text] [Related]
58. Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas.
Schepers K; Toebes M; Sotthewes G; Vyth-Dreese FA; Dellemijn TA; Melief CJ; Ossendorp F; Schumacher TN
J Immunol; 2002 Sep; 169(6):3191-9. PubMed ID: 12218137
[TBL] [Abstract][Full Text] [Related]
59. Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control.
Hwang ML; Lukens JR; Bullock TN
J Immunol; 2007 Nov; 179(9):5829-38. PubMed ID: 17947656
[TBL] [Abstract][Full Text] [Related]
60. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
